Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Market Gems:Stocks w/Strong Earnings and High Tech. Rank -- Ignore unavailable to you. Want to Upgrade?

To: sherlockgerlach who wrote (39511)	5/12/1999 1:28:00 AM
From: Jenna	Read Replies (6) \| Respond to of 120523

BXM.. You know what they say and URL is worth a thousand words. biz.yahoo.com I think you will find this link pretty impressive. Among other things to look at is the 5 quarter earnings surprises, the upgrade in earnings estimate only within the last 7 days, the triple digit growth, etc. Of course that is just the beginning of a research but the next part is a bit harder for me to decipher, but I will. Looks like a potential winner. I get into these pretty slowly but once it I stay a while. Now comes the hard part to understand if this procedure is accepted, will work, the market etc.. right now It's a trading or position hold kind of stock, for anything more I'd give it another quarter. BXM: RATING UPGRADED FROM ACCUMULATE TO STRONG BUY 4/27/99 - Prudential Securities-Equity David Lippman BXM BXM: RATING UPGRADED FROM ACCUMULATE TO STRONG BUY R E S E A R C H N O T E S April 27, 1999 Subject: Biomatrix, Inc. (BXM-33)--NYSE PHARMS COM EPS REC OPINION Current: STRONG BUY Analysts: David Lippman, CFA (212) 778-4994 Prior: ACCUMULATE Moiralee O'Leary (212) 778-2711 Risk: HIGH 18 Month Target price: $50 --------------------------------------------------------------------------- Ind. Div.: Nil Yield: Nil Shares: 22.6 mil. 52-Wk.Range: 45-12 --------------------------------------------------------------------------- EPS FY Year P/E 1Q 2Q 3Q 4Q Actual 12/98 $ 0.43A $ 0.04A $ 0.05A $ 0.07A $ 0.27A Current 12/99 $ 0.85E 38.8X $ 0.14A $ 0.14E $ 0.33E $ 0.25E Current 12/00 $ 1.69E 19.5X $ 0.30E $ 0.33E $ 0.57E $ 0.50E Full-Year EPS Does Not Add Due To Rounding. --------------------------------------------------------------------------- The shares of Biomatrix have declined recently apparently in response to first-quarter 1999 earnings results which indicated that in the United States, American Home Products, Biomatrix's marketing partner for Synvisc,shipped fewer prefilled syringes than in the fourth quarter of 1998. We believe that there will be an increase in American Home's shipments of Synvisc in the second quarter but that the increase will not be dramatic until or unless a direct-to-consumer campaign, scheduled to begin in June, creates a higher level of consumer demand. The marketing of Synvisc has been heavily concentrated on orthopedists and rheumatologists although there is a plan to include general practitioners in the marketing effort. Notwithstanding these programs, we believe that the potential market, which is believed to be in excess of 10 million patients, has barely been tapped when one considers the number of patients in the United States alone with osteoarthritis of the knee. In our opinion, a significant portion of these patients would be candidates for Synvisc therapy and if one assumes that only one million of these patients were treated annually with Synvisc, this would imply shipments of 3 million prefilled syringes per year, compared with the current sales rate of about 800,000.